Synaptic abnormalities, perturbed endosomal recycling mediated by loss of the small GTPase RAB11, and neuroinflammatory signaling have been associated with multiple neurodegenerative diseases including the motor neuron disease, amyotrophic lateral sclerosis (ALS). This is consistent with the neuroprotective effect of RAB11 overexpression as well as of anti-inflammatory compounds. However, most studies were in animal models, and this phenomenon has not been demonstrated in human patients. Moreover, crosstalk between endosomal trafficking and inflammatory signaling pathways in ALS remains enigmatic. Here, we investigated RAB11 expression and MAPK/ERK/AKT signaling in 10 post-mortem spinal cord specimens from patients with sporadic ALS and agematched controls. All 10 ALS patients showed TDP-43 pathology, whereas two specimens showed an overlapping FUS pathology and one had an acquired Q331K mutation in TDP-43. There was consistent RAB11 downregulation in all ALS cases, while p-AKT and phospho-ribosomal S6 kinase (p-p90RSK) were upregulated. Furthermore, competition between AKT and ERK pathways was observed in ALS, suggesting subtle differences among the TDP-43-ALS subtypes, which may influence patient therapeutic responses. Our findings demonstrate a complex regulation/perturbation pattern of signaling cascades involving MAPK/AKT/RAB11 in spinal cord tissue from ALS patients. These results underscore the relationships between ALS pathology, altered neuronal trafficking, and inflammation.
Main text
Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disorder of motor neurons. The major subtype of ALS (9 7% of cases) is associated with TAR DNA binding protein of 43 kDa (TDP-43) proteinopathy characterized by nucleo-cytosolic mislocalization [1] . Synaptic dysfunction and loss of vesicular trafficking have emerged as vital early factors in the etiologies of neurodegenerative diseases involving protein aggregates, which may develop decades before overt motor symptoms [2] . The endosomal recycling factor RAB11 (Ras-related protein) is a critical member of the Rab family; these small GTPases act as master-regulators for axonal transport of neurotrophin receptors and β1 integrins in dorsal root ganglion neurons, which is essential for their development, survival, and functionality [3] . Rab GTPase dysregulation has been consistently linked to defective vesicular trafficking, endosomal recycling, and autophagy in neurodegeneration [4] . Recent studies identified inhibition of endosomal trafficking due to loss of TDP-43 [5] and these defects were salvaged by RAB11 expression [6] . Furthermore, RAB11 signaling may crosstalk with essential immune-signaling pathways like mitogen-activated protein kinases/ extracellular signal-regulated kinase 1 and 2 (MAPK/ ERK1/2), as well as modulate AKT (protein kinase B)-mediated neuroinflammation [7] . Although initial activation by their respective tyrosine/serine phosphorylation is protective, persistent activation eventually promotes apoptosis.
In this report, we investigated the correlation between RAB11 loss and AKT/ERK signaling in post-mortem spinal cord tissue from patients with sporadic ALS. Ten ALS and four age-matched control samples were obtained from the Department of Veterans Affairs Brain Biorepository (USA). As tabulated in Fig. 1i and documented in our recent publication [8] , all 10 ALS specimens showed strong TDP-43 pathology, whereas two (#6 and #7) exhibited overlapping TDP-43 and FUS (another RNA/ DNA-binding ALS protein) pathology [9] . ALS#6 also harbored a Q331K mutation in the TARDBP gene that encodes TDP-43 [10] . We recently reported that loss of functional TDP-43 and FUS in these patients is linked to genome damage accumulation and apoptosis due to defective DNA strand-break repair [8, 9] . Here, we performed immunoblotting of total protein extracts isolated from cervical spinal cord tissues using the pathway-specific antibody cocktail (Abcam, Cat#ab151279) to assess RAB11 levels and its relationship with AKT/ERK signaling. RAB11 protein levels were decreased in all ALS cases [at least 2-fold on average, mean ± standard deviation (SD)] compared with controls (Figs. 1a and b) . Interestingly, in majority of ALS specimens with higher loss of monomeric TDP-43 and more aggregation (ALS #9 and #10) [8] showed significantly reduced RAB11 levels (Additional file 1: Figure S1 ), suggesting that impaired RAB11-mediated protein clearance may contribute to TDP-43 toxicity. However, the inconsistency in direct correlation between TDP-43 proteinopathy and loss of RAB11 in some cases may be due to their complex crosstalk and underlying secondary pathology, for example, Senataxin (SETX) (chr9:135202108 T > C) pathology in ALS#10 and C9ORF extension in ALS#3. AKT activation by phosphorylation at serine 473 (p-AKT) is critical for synaptic function and managing oxidative stress-associated neuroinflammation. TDP-43-ALS cases showed~4-fold (mean ± SD) higher levels of p-AKT (Figs. 1a, and c) , which was distinct from the mutant SOD1-ALS subtype [11] . Notably, the highest p-AKT level (≥6-fold) was observed in the ALS#6 spinal cord bearing a sporadic mutation of Q331K in TDP-43 that was associated with increased TDP-43 fragmentation along with overlapping FUS pathology [9, 10] . Furthermore, the activated forms of ERK1 (phosphorylated at tyrosine 204) and ERK2 (phosphorylated at tyrosine 187) were~6-fold (mean ± SD) higher in ALS cases compared with controls (Figs. 1a, d and e) . The p-AKT levels inversely correlated with p-ERK1/2 in ALS, although both were higher compared with controls (Fig. 1f) . This was most evident in ALS#3, #4, and #5 versus #6 and #8. It is also consistent with previous studies that show a negative regulation between AKT and ERK signaling pathways, even though they have a common downstream factor p90 ribosomal S6 kinase (p90RSK) [12, 13] . Hyperactivation of ERK1/2 signaling has been shown to contribute to neuronal cell cycle re-entry [14, 15] . Based on this, we speculate that such a phenotype may develop in subset of ALS patients with predominant ERK pathway activation, which may be addressed in future study. Independent of the extent of AKT or ERK1/2 signaling, p90RSK phosphorylation (serine 380) was significantly higher (≥8-fold, mean ± SD) in all ALS cases (Figs. 1a and g ). Furthermore, although overall fold-changes of p-AKT and p-p90RSK proteins were higher in ALS patients compared with controls, ALS#6 patient with a TDP-43 Q331K mutation had the highest level of p-AKT and downstream factor pp90RSK but comparable levels of p-ERK1/2. The total AKT and ERK1/2 levels were comparable in ALS specimens or controls (Additional file 2: Figure S2) .
The inverse correlation between p-AKT and p-ERK1/2 levels is likely dependent on the underlying pathology, including TDP-43 aggregation versus fragmentation phenotype and/or its overlap with either FUS, C9ORF72 or SETX pathology. This reveals the complexity of the disease mechanisms and underscores the dynamic crosstalk involving direct or inverse relationships between these pathways.
In conclusion, our study shows overall dysfunction in a complex network of signaling cascades involving MAPK/AKT/RAB11 pathways associated with neurodegeneration in ALS (summarized in Fig. 1h ). As highlighted in our comprehensive review of complexity in ALS subtypes [1] , there are substantial differences in the underlying pathologies of a dozen ALS subtypes. Consistently, our results emphasize subtle differences and the complex regulation among signaling pathways in TDP-43 and, C9ORF72-, SETX-or FUS-associated overlapping ALS pathologies, which may provide clue on enigmatic ALS disease mechanisms for further investigation and therapeutic considerations. 
